TRT and hormone therapy programs, under your brand

EPCS and the DEA telemedicine flexibilities

Prescribing a Schedule III product electronically requires an EPCS-capable system with two-factor authentication and identity-proofed prescribers.

• Separately, the DEA and HHS extended the COVID-era telemedicine flexibilities a fourth time, through December 31, 2026, which lets DEA-registered practitioners prescribe Schedule II through V medications by audio-video telemedicine without a prior in-person exam.
• The DEA has said it intends to publish a final rule before that date.
• Any program launched today should be built so it can add an in-person or special-registration step if the final rule requires one.

Two labs before a diagnosis

The American Urological Association guideline defines testosterone deficiency as a total testosterone consistently below 300 ng/dL on at least two early-morning measurements taken on separate occasions, paired with symptoms or signs.

A program that prescribes off a single value, or off symptoms alone, is out of step with the guideline and exposed on review. Your medical director may set a stricter protocol, but two morning draws is the floor we build into the intake flow.

State licensure and telehealth practice standards

The prescribing provider must hold a license in the state where the patient is located at the time of the visit, and several states impose their own telehealth rules for controlled substances, including video requirements, additional PDMP checks or in-person visit expectations.

Coverage across all 50 states means the network can route a visit to a provider licensed for that patient, and OrbitOS applies state rules at intake rather than after the fact.

Monitoring obligations after the first prescription

In February 2025 the FDA issued class-wide labeling changes for testosterone products: the boxed warning on cardiovascular risk was revised in light of the TRAVERSE trial, and a new warning about blood pressure increases was added.

Standard follow-up for a TRT patient therefore includes recheck testosterone, hematocrit, PSA where indicated and blood pressure. A program with no recheck workflow is not a clinic; it is a supply channel, and regulators treat it that way.

HRT for women and menopause programs

Estradiol, progesterone and most menopause therapies are not controlled substances, so the DEA layer does not apply, but the same practice standards do: a licensed provider, a documented history including contraindications, an informed decision about route and dose, and a recheck plan.

Compounded bioidentical products carry their own labeling and marketing limits. As of September 2026, FDA has been re-examining the class labeling for menopausal hormone therapy; your medical director should track that rather than rely on this page.

Marketing, corporate practice and the merchant of record

Most states restrict who can own a medical practice and how a lay company can share in professional fees.

MyOrbitHealth runs the managed-services structure so the licensed practice makes clinical decisions and your brand handles marketing, technology and patient acquisition. Your brand is the merchant of record and owns the patient relationship and data; there is no revenue share tied to prescribing volume, which is the arrangement that draws the most scrutiny in this category.

Orbit Intake for hormone patients

Branded questionnaires for low testosterone, andropause symptoms, perimenopause and menopause, plus identity verification and state detection.

Intake captures the history a provider needs to rule out contraindications and flags anything that should stop a prescription before the visit is scheduled.

Orbit Labs, drawn three ways, for baseline and rechecks

A provider orders the baseline panel.

• The patient collects it as a Quest or Labcorp walk-in with an order slip, a Tasso at-home kit shipped by FedEx, or a mobile phlebotomy visit.
• For the second morning draw the guideline expects, the same three options apply, which is what keeps completion rates up.
• Results route to the ordering provider, who reads them into the plan; the patient sees an interpreted result, not a raw PDF.
• Your storefront can also carry a patient self-order lab catalog for people who want a testosterone test at home before they commit to a visit.

Provider Network licensed in all 50 states

2,400+ board-certified MDs, DOs, NPs and PAs across 38+ specialties, credentialed to NCQA standards with monthly OIG and SAM screening, available 24 hours, with an average response under six minutes during business hours.

Every prescriber who touches a controlled substance has completed EPCS identity proofing and holds a DEA registration.

OrbitRx with EPCS to 503A and retail pharmacies

Prescriptions leave OrbitRx through Surescripts with EPCS two-factor sign-off.

Testosterone cypionate and enanthate, gels, estradiol, progesterone, anastrozole, hCG where clinically appropriate and other ancillaries route to a LegitScript-certified 503A compounding or retail pharmacy, with cold chain for products that need it. Medication is passed through at 0% markup.

OrbitOS for the operator

One console for encounters, orders, lab status, refills, recheck reminders and patient messages.

Your team sees who is overdue for a recheck, which kits have not come back, which refills are waiting on a provider and where turnaround is slipping. Nothing clinical is editable by the brand; everything operational is visible.

Storefront, app and developer surface

A branded storefront with checkout and subscriptions, a native iOS and Android app, and a REST API with webhooks and a React SDK for teams that want to keep their own front end.

A public MCP server lets your internal tools query program state. Managed LegitScript certification for your brand is included: we prepare, file and manage the application through approval, typically days once filed, with the decision resting with LegitScript.